ObjectiveTo survey the clinical application of glycopeptide antibiotics in hospitalized patients, and evaluate the rationality of drug use, so as to provide reference for rational clinical drug use. MethodsA retrospective study was conducted to investigate the application of glycopeptide antibiotics among inpatients in a hospital from January to December in 2014, relevant clinical data were recorded. ResultsA total of 727 cases were included , 471 (64.79%) of which were infected cases. Respiratory tract infection was the main site of both healthcareassociated infection and communityassociated infection (39.17% and 45.98%, respectively). The average days of glycopeptide antibiotic use were 6.06 day (4 403/727). Patients who used glycopeptide antibiotics were mainly from intensive care unit, department of oncology, and department of neurosurgery, accounting for 20.36%(n=148) , 12.10%(n=88), and 11.14%(n=81) respectively. Glycopeptide was used in 338 patients（46.49%），the average types of combined use was 4.43, triple and above was used in 99 patients（13.62%），combination of the second generation cephalosporins was the highest(20.48%）. 450（61.90%） patients used vancomycin, 260（35.76%）used teicoplanin，17（2.34%）used both vancomycin and teicoplanin. A total of 847 pathogenic strains were isolated, the major were Acinetobacter baumannii (n=111, 13.10%), Klebsiella pneumoniae (n=80, 9.45%), Pseudomonas aeruginosa (n=68, 8.03%), and Staphylococcus aureus (n=54 , 6.37%), methicillinresistant Staphylococcus aureus was 50 strains. 490 (67.40%) patients treated with glycopeptide antibiotics were effective. Of 727 patients, 86 (11.83%) used antibiotics rationally, 315（43.33%） basically rational，and 326 (44.84%) irrationally. ConclusionApplication of glycopeptide antibiotics in this hospital is basically rational, but indications should be paid attention.